Beckman Coulter has been gained rights to develop and jointly market the MeMed BV test on its Access Family of Immunoassay Analyzers
Beckman Coulter Diagnostics, a part of Danaher, and MeMed have announced a partnership to co-develop and commercialise the latter’s MeMed BV test, a host immune response diagnostic.
MeMed, which is based in Israel, has designed the MeMed BV test to distinguish between bacterial and viral infections.
According to the terms of the collaboration, Beckman Coulter has been given rights to develop and jointly market the MeMed BV test on its Access Family of Immunoassay Analyzers.
Beckman Coulter president Julie Sawyer Montgomery said: “We are thrilled to be partnering with MeMed to make this novel test available to millions of patients through our Access Family of Immunoassay Analyzers.
“The ability to distinguish between bacterial and viral infections early in the diagnostic process has significant potential to impact patient care, as well as combat antimicrobial resistance.”
MeMed has developed the BV test to support the management of patients with acute infections in a variety of clinical settings, including emergency departments.
The MeMed BV test utilises machine learning for integrating measurements of three important host-immune proteins TRAIL, IP-10, and CRP to produce a score that indicates the risk of bacterial or viral infections.
The test’s performance is said to have been verified using MeMed Key, a compact immunoassay platform in over 20,000 patients in various blinded validation studies and in real-world use, said Beckman Coulter.
MeMed BV on MeMed Key has received US Food and Drug Administration (FDA) clearance, CE-marking, as well as Israeli Ministry of Health’s approval.
MeMed CEO and co-founder Eran Eden said: “Our vision for MeMed BV is that it becomes standard of care, enabling significant improvements in patient management to address the urgent global antimicrobial resistance threat.
“We believe that forging a strategic alliance with an industry leader, such as Beckman Coulter, will expedite the realisation of this vision and support better clinical, operational, and financial outcomes for healthcare systems globally.”